The Caris gene expression assay performed earlier demonstrated a potential therapeutic benefit of sunitinib due to the upregulation of VEGFR2. Sunitinib was then started at 50 mg daily and within 2 months the patient had a complete resolution of all her tumors (Fig. 1B). Fifteen months after the enactment of sunitinib, the patient is disease free, on a maintenance dose of 25 mg daily of sunitinib.